Trevi Therapeutics, Inc.
TRVI · XNASCIK 1563880fmd_1CTVDCH0G6K99ZF9M2RHKY7D3FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 14 | 19 | 22 | 23 | 20 | 24 | 39 | 33 |
| Total operating expenses | 18 | 27 | 32 | 32 | 30 | 34 | 52 | 49 |
| Operating income | (18) | (27) | (32) | (32) | (30) | (34) | (52) | (49) |
| Interest expense | 0 | – | 0 | 1 | 1 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | 5 | 4 | 7 |
| Other non-operating income (expense) | (2) | 1 | (0) | (1) | 1 | 5 | 4 | 7 |
| Income before taxes | (21) | (26) | (33) | (34) | (29) | (29) | (48) | (43) |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| Net income from continuing operations | (21) | (26) | (33) | (34) | (29) | (29) | (48) | (43) |
| Net income | (21) | (26) | (33) | (34) | (29) | (29) | (48) | (43) |
| Net income to common shareholders | (26) | (27) | (33) | – | – | – | – | – |